TW201139446A - Furopyridine compounds and uses thereof - Google Patents

Furopyridine compounds and uses thereof Download PDF

Info

Publication number
TW201139446A
TW201139446A TW100113755A TW100113755A TW201139446A TW 201139446 A TW201139446 A TW 201139446A TW 100113755 A TW100113755 A TW 100113755A TW 100113755 A TW100113755 A TW 100113755A TW 201139446 A TW201139446 A TW 201139446A
Authority
TW
Taiwan
Prior art keywords
methyl
group
cyclopropyl
fluorophenyl
ethyl
Prior art date
Application number
TW100113755A
Other languages
English (en)
Chinese (zh)
Inventor
David Barnes
Rajiv Chopra
Scott Louis Cohen
ji-ping Fu
Mitsunori Kato
Pei-Chao Lu
Mohindra Seepersaud
Wei Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW201139446A publication Critical patent/TW201139446A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
TW100113755A 2010-04-21 2011-04-20 Furopyridine compounds and uses thereof TW201139446A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32649110P 2010-04-21 2010-04-21

Publications (1)

Publication Number Publication Date
TW201139446A true TW201139446A (en) 2011-11-16

Family

ID=44010017

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100113755A TW201139446A (en) 2010-04-21 2011-04-20 Furopyridine compounds and uses thereof

Country Status (9)

Country Link
US (1) US8324239B2 (enExample)
EP (1) EP2560976B9 (enExample)
JP (1) JP5756850B2 (enExample)
CN (1) CN103025738B (enExample)
AR (1) AR082453A1 (enExample)
ES (1) ES2605039T3 (enExample)
TW (1) TW201139446A (enExample)
UY (1) UY33348A (enExample)
WO (1) WO2011131709A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013009789A2 (pt) * 2010-10-26 2016-07-19 Presidio Pharmaceuticals Inc inibidores do vírus da hepatite c
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
BR112017023821A2 (pt) 2015-05-06 2018-07-31 Leidos Biomedical Res Inc moduladores de k-ras
BR112019021899A2 (pt) 2017-04-20 2020-08-18 The Regents Of The University Of California moduladores de k-ras
KR102659322B1 (ko) * 2017-05-19 2024-04-22 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 융합된 헤테로방향족-아닐린 화합물
WO2019204449A1 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfone moiety
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383A (en) 1846-02-10 Improvement in condensing steam and feeding steam-boilers
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
DK0527788T3 (da) 1990-04-04 2004-09-06 Chiron Corp Hepatitis C virus protease
ATE355380T1 (de) 1993-04-02 2006-03-15 Rigel Pharmaceuticals Inc Methode zur selektiven inaktivierung der viralen replication
IT1272179B (it) 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5703116A (en) 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
US5861267A (en) 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
JP4191797B2 (ja) 1995-09-27 2008-12-03 エモリー ユニバーシティー 組み換えc型肝炎ウイルスrnaレプリカーゼ
US5759795A (en) 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region
CA2312484A1 (en) 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JPWO2002051849A1 (ja) 2000-12-26 2004-04-22 第一製薬株式会社 Cdk4活性阻害剤
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
US20050069522A1 (en) 2002-08-12 2005-03-31 Richard Colonno Combination pharmaceutical agents as inhibitors of HCV replication
BR0315233A (pt) 2002-10-09 2005-08-23 Scios Inc Derivados de azaindol como inibidores de p38 cinase
HN2003000348A (es) 2002-11-01 2008-10-14 Viropharma Inc Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
MXPA05010802A (es) 2003-04-25 2005-12-14 Univ Cardiff Compuestos heterociclicos para el uso en el tratamiento de infecciones virales.
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
WO2005072412A2 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
JPWO2005082905A1 (ja) 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
US7846959B2 (en) 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
JP5026963B2 (ja) 2004-06-22 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド カルシウムチャネル調整用の複素環誘導体
TW200618800A (en) 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP2008517896A (ja) 2004-10-21 2008-05-29 ファイザー・インク C型肝炎ウイルスプロテアーゼの阻害剤並びにそれを用いた組成物及び治療
EP1948137A2 (en) 2005-11-10 2008-07-30 Wyeth a Corporation of the State of Delaware Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-(2-hydroxyethyl)(methylsulfonyl) amino-n-methyl-1-benzofuran-3-carboxamide and method of making same
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2008011557A2 (en) 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
MX2009008439A (es) 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
TW200900408A (en) 2007-03-02 2009-01-01 Kyowa Hakko Kogyo Kk Fused pyridine derivative
PE20090142A1 (es) 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
WO2008128995A1 (en) 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
KR101596524B1 (ko) 2007-06-29 2016-02-22 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
WO2009041591A1 (ja) 2007-09-28 2009-04-02 Kyowa Hakko Kirin Co., Ltd. 縮環ピリジン誘導体
CN101910145A (zh) 2008-02-14 2010-12-08 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
US8324239B2 (en) 2012-12-04
AR082453A1 (es) 2012-12-12
JP2013527842A (ja) 2013-07-04
JP5756850B2 (ja) 2015-07-29
EP2560976B9 (en) 2017-06-07
CN103025738B (zh) 2015-08-19
ES2605039T3 (es) 2017-03-10
CN103025738A (zh) 2013-04-03
US20120015907A1 (en) 2012-01-19
EP2560976B1 (en) 2016-08-24
EP2560976A1 (en) 2013-02-27
WO2011131709A1 (en) 2011-10-27
UY33348A (es) 2011-12-01

Similar Documents

Publication Publication Date Title
ES2897913T3 (es) Compuestos de piridona tetracíclicos como antivirales
ES2940263T3 (es) Compuestos químicos
ES2660914T3 (es) Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
CN103561576B (zh) 脂质合成的杂环调节剂
TW201139446A (en) Furopyridine compounds and uses thereof
ES2784477T3 (es) Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
EP3083583B1 (en) Heterocyclic modulators of lipid synthesis and combinations thereof
KR20210110566A (ko) 인돌 ahr 저해제 및 이의 용도
AU2017281903A1 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US20210214366A1 (en) Bicyclic heterocycles as fgfr inhibitors
CN111801331A (zh) 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
CA2828478A1 (en) Serine/threonine kinase inhibitors
US20210206760A1 (en) Phenyl-substituted dihydronaphthyridine compound and use thereof
TW201014855A (en) Compounds for the treatment of hepatitis C
TW200946531A (en) HSP90 inhibitors
TW200924751A (en) 2,3-substituted indole derivatives and methods of use thereof
TW201211032A (en) Hepatitis C virus inhibitors
US20240150343A1 (en) Compound having brd4 inhibitory activity, preparation method therefor and use thereof
TW200936591A (en) Tricyclic compounds and use thereof
TW201632514A (zh) 作為丙型肝炎抑制劑的化合物及其在藥物中的應用
TW201011030A (en) Tricyclic indole derivatives and methods of use thereof
US20230391752A1 (en) Pyrrolidine-3-carboxamide derivatives and related uses
CN109721536B (zh) 苯基取代的稠合三环类化合物及其用途
ES2757052T3 (es) Derivados heterocíclicos bicíclicos
US8716275B2 (en) Compound for the treatment of hepatitis C